Gene therapy for cystic fibrosis (CF) has great appeal, but initial results with viral vectors and lipid-mediated gene transfer has been disappointing, so alternative strategies will be necessary. Molecular conjugates directed at the serpin-enzyme complex receptor (SEC-R) have been effectively used to correct the Cl transport defect found in the nasal epithelium of CF mice. The molecular conjugates are comprised of a peptide ligand for the SEC-R covalently bound to polylysine. This complex binds to DNA through charge interactions, and the complete conjugate is ultimately condensed under high salt conditions. Correction of the ion transport defect is not observed when the DNA is condensed with polylysine without ligand or if the ligand complex is conjugated with the lac Z gene. The conditions for transfer to the nasal epithelium will be optimized and assessment of the Cl ion transport defect will be carried out with respect to its relationship to the increased Na absorption and the reduced expression of nitric oxide synthetase-2 (NOS-2) also associated with the mutation in mouse CFTR. In addition, the conditions for gene delivery to the trachea will also be determined in the context of a correction in the Cl transport defect. The impact of the correction in Cl transport in the lower airways will be correlated with any increases in NOS-2, IL-10 expression and a reduction in the hyper-inflammatory response associated with Pseudomonas challenge in the CF animals. Toxicity and the effects of repeated dosing will also be assessed. Finally, the SEC-R complexes will be intravenously injected and applied directly to measure gene transfer into alveolar macrophages and the airway luminal epithelium, respectively. Delivery of CFTR into the airways and the alveolar macrophages will be analyzed in terms of protection against the inflammatory response to Pseudomonas. This analysis will determine whether the CF epithelium or the macrophages are responsible for the excessive inflammatory response. If the project is successful a new gene transfer strategy for CF and other airway diseases will be developed and the role of CFTR delivery to the epithelium in mediating the secondary phenotypic consequences of CF.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK058318-02
Application #
6381859
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Mckeon, Catherine T
Project Start
2000-09-01
Project End
2004-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
2
Fiscal Year
2001
Total Cost
$265,431
Indirect Cost
Name
Case Western Reserve University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21
Sun, Wenchao; Fletcher, David; van Heeckeren, Rolf Christiaan et al. (2012) Non-covalent ligand conjugation to biotinylated DNA nanoparticles using TAT peptide genetically fused to monovalent streptavidin. J Drug Target 20:678-90
Sun, Wenchao; Davis, Pamela B (2010) Reducible DNA nanoparticles enhance in vitro gene transfer via an extracellular mechanism. J Control Release 146:118-27
Rhee, Melanie; Davis, Pamela (2006) Mechanism of uptake of C105Y, a novel cell-penetrating peptide. J Biol Chem 281:1233-40
Davis, Pamela B (2006) Cystic fibrosis since 1938. Am J Respir Crit Care Med 173:475-82
Ziady, Assem-Galal; Gedeon, Christopher R; Miller, Timothy et al. (2003) Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 8:936-47
Ziady, Assem-Galal; Gedeon, Christopher R; Muhammad, Osman et al. (2003) Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther 8:948-56